AVI CO 004

Drug Profile

AVI CO 004

Alternative Names: AVI-CO-004

Latest Information Update: 29 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Avixgen
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV-1 infections
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I HIV-1 infections

Most Recent Events

  • 18 Aug 2017 Ebixen announces intention to submit phase II IND to Korea FDA for HIV-1 infections
  • 18 Aug 2017 Ebixen plans a phase II trial for HIV-1 infections in South Korea (PO)
  • 09 Mar 2017 Avixgen initiates enrolment in a phase I trial In Volunteers in South Korea (KCT0002279)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top